Patents Assigned to TILT BIOTHERAPEUTICS OY
  • Oncolytic adenoviruses coding for bi-specific antibodies
    Patent number: 11485791
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to an oncolytic adenoviral vector encoding a bispecific monoclonal antibody. Furthermore, the present invention relates to methods and uses utilizing the oncolytic adenoviral vectors, also together with adoptive cell therapies.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: November 1, 2022
    Assignee: TILT Biotherapeutics Oy
    Inventors: Akseli Hemminki, Suvi Parviainen, Siri Tähtinen, Ilkka Liikanen, Mikko Siurala
  • Enhanced adoptive cell therapy
    Patent number: 10787645
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 29, 2020
    Assignee: TILT Biotherapeutics Oy
    Inventors: Akseli Hemminki, Markus Vähä-Koskela, Siri Tähtinen, Vincenzo Cerullo
  • Enhanced adoptive cell therapy
    Patent number: 10647963
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: May 12, 2020
    Assignee: TILT BIOTHERAPEUTICS OY
    Inventors: Akseli Hemminki, Markus Vaha-Koskela, Siri Tahtinen, Vincenzo Cerullo